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Introduction: KRAS mutations are poor prognostic markers for 
patients with non–small-cell lung cancer (NSCLC). RALA and 
RALB GTPases lie downstream of RAS and are implicated in RAS-
mediated tumorigenesis. However, their biological or prognostic role 
in the context of KRAS mutation in NSCLC is unclear.
Methods: Using expression analysis of human tumors and a panel of 
cell lines coupled with functional in vivo and in vitro experiments, 
we evaluated the prognostic and functional importance of RAL in 
NSCLC and their relationship to KRAS expression and mutation.
Results: Immunohistochemical (N = 189) and transcriptomic (N = 337) 
analyses of NSCLC patients revealed high RALA and RALB expres-
sion was associated with poor survival. In a panel of 14 human 
NSCLC cell lines, RALA and RALB had higher expression in 
KRAS mutant cell lines whereas RALA but not RALB activity was 
higher in KRAS mutant cell lines. Depletion of RAL paralogs identi-
fied cell lines that are dependent on RAL expression for prolifera-
tion and anchorage independent growth. Overall, growth of NSCLC 
cell lines that carry a glycine to cystine KRAS mutation were more 
sensitive to RAL depletion than those with wild-type KRAS. The 
use of gene expression and outcome data from 337 human tumors 
in RAL-KRAS interaction analysis revealed that KRAS and RAL 
paralog expression jointly impact patient prognosis.
Conclusion: RAL GTPase expression carries important addi-
tional prognostic information to KRAS status in NSCLC patients. 
Simultaneously targeting RAL may provide a novel therapeutic 
approach in NSCLC patients harboring glycine to cystine KRAS 
mutations.
Key Words: RAL, RAS, Non–small-cell lung cancer, GTPase, 
Prognosis.
(J Thorac Oncol. 2013;8: 1492–1501)
In the United States, 228,190 new diagnoses and 159,480 lung cancer deaths are projected for 2013.1 Worldwide lung 
cancer is also the leading cause of cancer death.1 Historically, 
therapy has been guided by tumor histology. Yet, despite recent 
advances, overall survival in the United States remains 16% 
at 5 years for non–small-cell lung cancer (NSCLC), a group 
composed of adenocarcinoma, squamous cell carcinoma, and 
large-cell carcinoma subtypes. During the past decade, unique 
genetic changes have been observed in NSCLCs2–5 and used 
for both prognostication and therapeutic decision making 
using targeted agents.
RAS mutations are found in 25% to 40% of NSCLCs,5–7 
with KRAS mutations accounting for 90%. Approximately 97% 
of KRAS mutations in NSCLC involve codon 12 or 138 and 
are a negative prognostic marker for patients with NSCLC.9 
Unfortunately, direct RAS targeted therapy is not clinically avail-
able.4,5 An alternate strategy is targeting signal proteins down-
stream of RAS. RAS proteins signal primarily through three 
cascades; MAPK, PI3K/AKT, and RAL GTPase.2,5 Inhibitors 
of the MAPK and PI3K/AKT pathway are in various stages 
of clinical trials for treatment of NSCLC patients with KRAS 
mutations.5 Because no compelling clinical rationale exists for 
RAL targeting in cancer, no therapies have been developed.
RAL GTPases are critical drivers of human oncogen-
esis with vital roles in tumor growth and migration in pan-
creatic, prostate, colorectal, and bladder cancers.10–13The RAL 
GTPase family comprises RALA and RALB paralogs, which 
share 85% amino acid sequence homology.14 Despite similar 
structures and downstream effectors they have differential 
effects on cancer cell phenotypes in different tumor models.14 
Recently, a KRAS driven NSCLC mouse model showed RAL 
GTPase is required for tumorigenesis.15 However, the impor-
tance of RAL as a prognostic marker and its functional impor-
tance with respect to KRAS expression and mutation status in 
human NSCLC is unknown.16 Here we combine for the first 
time transcriptomic and immunohistochemical (IHC) analy-
ses on human samples with molecular manipulation and eval-
uation of RAS and RAL in human NSCLC cell lines to show 
that RALA and RALB are both important prognostic factors 
in NSCLC and drive tumor growth in vivo. Our work pro-
vides the rationale for thinking that simultaneous inhibition 
of MAPK, PI3K/AKT, and RAL pathways would be effective 
treatment of patients with KRAS mutations5 and impetus for 
drug development directed at the RAL pathway.
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MATERIALS AND METHODS
Cell Lines and Biochemical Reagents
NSCLC cell lines H358, H2122, H460, A549, H157, 
Calu-6, SW1573, H2009, H2228, H1703, HCC4006, Calu-
3, H322, and H292 were obtained from the American Type 
Culture Collection (Manassas, VA) and cultured in Roswell 
Park Memorial Institute (RPMI)-1640 (Invitrogen, Grand 
Island, NY) supplemented with 10% fetal bovine serum 
as recommended by American Type Culture Collection. 
Small interfering RNA (siRNA) targeting RALA (siRALA, 
5′-GACAGGUUUCUGUAGAAGA-3′), RALB (siRALB, 
5′-AAGCUGACAGUUAUAGAAA-3′), or both (siRALA+B, 
5′-GACUAUGAACCUACCAAAG-3′) were obtained as previ-
ously described.17 A second set of siRNA against RALA (siRALA 
II, 5′-CAGAGCUGAGCAGUGGAUU-3′) and RALB (siRALB 
II, 5′-GGUGAUCAUGGUUGGCAGC-3′) was also used. A non-
specific siRNA (siCTL, 5′-CGTACGCGGAATACTTCGA-3′) 
was used as control for all the experiments.17 All siRNAs were 
from Dharmacon (Lafayette, CO). Cells were transduced with 
siRNA (200 nmol per liter) by using oligofectamine (Invitrogen) 
according to the manufacturer’s instructions. KRAS wild-type 
(WT) and KRAS G12C and G12V mutant constructs were from 
the Missouri S&T cDNA Center (Rolla, MO).
Western Blotting, RAL, and 
KRAS Activation Assays
Cells were lysed using CelLytic™ Cell Lysis Reagent 
(Sigma-Aldrich, St. Louis, MO) and Westerns performed as 
previously described.17 Equal amounts of protein were subjected 
to sodium dodecyl sulfate-polycrylamide gel electrophoresis 
(SDS-PAGE), transferred to polyvinylidene difluoride (PVDF) 
membrane, and probed with antibodies against RALA (BD 
Transduction Laboratories, San Jose, CA), RALB (Millipore, 
Billerica, MA), α-Tubulin (Santa Cruz Biotechnology Inc., 
Santa Cruz, CA), extracellular-signal-regulated kinases (ERK) 
and phospho-ERK (pERK), AKT and phospho-AKT, and 
KRAS (all from Cell Signaling, Danvers, MA). RALA and 
RALB activity was measured using RAL Activation Assay Kit 
(Millipore). In brief, cell lysates were incubated with RALBP1 
agarose slurry for 4 hours at 4°C. After this the beads were 
washed and boiled in Laemmli Sample Buffer. The boiled 
samples are divided in half and run as two set of samples on 
SDS-PAGE followed by Western blotting. One set of sample 
was probed for RALA and the second for RALB.17 horse-
radish peroxidase (HRP) labeled mouse or rabbit secondary 
antibodies (Cell Signaling) were used to develop the blots by 
chemiluminescence by using enhanced chemoluminescence 
(ECL) (Pierce, Rockford, IL). KRAS activation assay was car-
ried out on H2228 cells stably transfected with empty vector, 
KRAS WT, KRAS G12C and G12V constructs by using RAS 
Activation enzyme-linked immunoabsorbent assay (ELISA) 
Kit (Millipore) following the manufacturer’s protocol.
Cancer Cell Growth In Vitro and In Vivo
For assessment of monolayer proliferation, 103 cells 
were plated in 96 well plates in triplicate or greater 48 hours 
after the cells were transduced with control siRNA (siCTL) 
or siRNA targeting RALA, RALB, or both (RALA+B). Cell 
numbers were determined daily by using the CYQUANT assay 
(Invitrogen) as directed by the manufacturer. For anchorage 
independent growth assessment, lines were plated in tripli-
cate in 0.4% agar (15,000 or 20,000 cells/well) 48 hours after 
siRNA transduction. At selected time points based on the 
colony-forming capacity of each cell line, colonies formed in 
soft agar were stained with Nitro-BT (Sigma-Aldrich) at 37°C 
overnight and counted using software ImageJ.18 For xenograft 
experiments, 4-week-old female athymic NCr-nu/nu mice were 
obtained from the National Cancer Institute (NCI-Frederick, 
Frederick, MD). At 6 to 8 weeks of age they were injected with 
H2122 cells (2 × 105 cells/site) transduced 48 hours earlier 
with RALA, RALB, RALA+RALB, or control siRNA in their 
left and right flanks, and monitored for subcutaneous tumor 
growth. Tumors were measured regularly as indicated in the 
results and tumor volume calculated as described.19
RAL IHC Analysis
Details on primary tumor samples and specific protocols 
for IHC sample preparation and RAL GTPase staining are in 
Supplementary Information (Supplementary Digital Content 
1, http://links.lww.com/JTO/A482). Membranous and cyto-
plasmic expression was scored separately, and the associa-
tion of RALA and RALB expression with patient outcomes 
(i.e., time to progression, overall survival, etc.) was performed 
by the University of Colorado Cancer Center Biostatistics 
and Bioinformatics Shared Resource by using SAS/BASE 
and SAS/STAT software, Version 9.2 of the SAS System for 
Windows (SAS Institute Inc., Cary, NC). Cox proportional 
hazards model was fit and the proportional hazards assump-
tion was checked and found to be met. The interaction between 
RALA and RALB protein expression was analyzed as well 
as the association to outcome of each protein alone, adjust-
ing for patient characteristics, stage (1/2/3/4), age, histology 
(adenocarcinoma, squamous cell carcinoma, NSCLC, not 
otherwise specified, mixed adenocarcinoma and squamous 
cell carcinoma characteristics [mixed], and sex (M/F). When 
analyzing the association between overall survival and the 
interaction between RALA and RALB, expression scores were 
dichotomized at their respective medians (i.e., low RALA+low 
RALB, low RALA+high RALB, high RALA+low RALB, 
high RALA+high RALB); when analyzing one protein alone, 
the expression score was categorized by its quartiles (lowest 
25%, 25%–50%, 50%–75%, highest 25% of scores)
Microarray Analysis
Three publicly available NSCLC patient data sets 
(Supplementary Table 3) were used. To examine whether 
RALA or RALB gene expression could stratify patient sur-
vival, patients were divided into two groups according to gene 
expression or risk scores and were compared by Cox propor-
tional hazards models and log-rank tests (see Supplementary 
Information, Supplementary Digital Content 1, http://links.
lww.com/JTO/A482). To analyze the interaction between 
KRAS and RAL genes, a patient was classified as either 
high- or low-expressing by using a gene’s median expression. 
Patient groups with different expression levels of KRAS and 
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RAL genes were compared by Cox proportional hazards mod-
els and log-rank tests.
RESULTS
RAL Expression Stratifies Prognosis 
in NSCLC Patients
It is well established that in cancerous cells there is more 
RAL-GTP versus RAL-GDP compared with normal cells 
and its role in various tumor types is acknowledged.10,14,17,20 
However, RAL expression as a prognostic biomarker in 
cancers is unclear.21 The role of RAL expression as a prog-
nostic biomarker in NSCLC is yet to be determined. We 
addressed this gap in the literature by investigating whether 
RAL expression determined by either IHC or transcriptomic 
analysis was prognostic in patients with NSCLC. The clini-
cal cohort used for the prognostic (IHC) study is described 
in Supplementary Table 1. Analysis of RALA and RALB 
membrane and cytoplasmic expression in the tumor samples 
revealed that NSCLC patients have variable degree of RAL 
GTPase membrane and cytoplasmic expression (Fig. 1A, C). 
There is higher cytoplasmic expression of RALA and RALB 
compared with membrane expression (p < 0.05; Fig. 1B, D). 
Also, RALA membrane expression is higher than RALB 
membrane expression (p < 0.0001; Fig. 1B, D). Because 
membrane localization of GTPases is canonically associated 
with higher activity14,20,22,23 these data suggest NSCLC speci-
mens harbor more activated RALA than RALB. Interestingly, 
RAL cytoplasmic and membrane expression does not change 
as a function of tumor stage and histology (Supplementary 
Figure 1, Supplemental Digital Content 2, http://links.lww.
com/JTO/A483). With IHC techniques established, the cor-
relation of RALA and RALB membrane and cytoplasmic 
expression with patient survival was evaluated. High RALA 
membrane expression (top 25% expression) trended toward 
poor overall survival when compared with low RALA mem-
brane expression (low 25% expression) though the data are 
not statistically significant (Fig. 2A, Supplementary Table 
2) whereas high RALB membrane expression (top 25% 
expression) was associated with poor overall survival when 
FIGURE 1.  RALA and B cytoplas-
mic and cell membrane immu-
nohistochemical staining in the 
NSCLC patient tumor samples. 
H-score was used to measure the 
staining for RAL protein expression 
(see Supplementary Materials and 
Methods section, Supplemental 
Digital Content 1, http://links.lww.
com/JTO/A482). The average H-score 
of the triplicate cores per patient was 
highly correlated to the core with the 
highest score from the same patient, 
thus further analyses were performed 
using the maximum H-score. A and 
C, Show typical examples of (i) low 
or no cytoplasmic and membranous 
protein; (ii) high membranous and 
low cytoplasmic; (iii) high cytoplas-
mic and high membranous staining 
for RALA and RALB. B and D, Show 
three graphical depictions of RALA 
and B membrane and cytoplas-
mic staining in NSCLC specimens. 
NSCLC, non–small-cell lung cancer.
1495Copyright © 2013 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 8, Number 12, December 2013 Contributions of KRAS and RAL
compared with low RALB membrane expression (bottom 
25% expression, p = 0.04; Fig. 2B, Supplementary Table 2). 
When we evaluated all four quartiles of RALA and B expres-
sion and effect on patient survival the data were not found 
to be statistically significant (Supplementary Figure 2A, B, 
Supplemental Digital Content 2, http://links.lww.com/JTO/
A483). Other mathematical constructs of RAL expression 
(with either each paralog separately or combined) such as 
membrane (data not shown), membrane/cytoplasm (data not 
shown), or membrane + cytoplasm (Supplementary Figure 
2C, D, Supplemental Digital Content 2, http://links.lww.com/
JTO/A483) among others did not offer enhanced predictive 
ability over individual analysis.
Next, we examined the prognostic importance of RAL 
mRNA expression in predicting NSCLC patient survival. 
Three public gene expression data sets of lung cancer patients 
were analyzed (Supplementary Table 3). In two of three 
data sets, patients with high RALA expression had poorer 
recurrence-free survival and overall survival in comparison 
to low RALA expression (Fig. 2Ci and Cii). High RALB 
mRNA expression was also prognostic of poor overall sur-
vival in one of three data sets (Fig. 2D). When we evaluated 
all four quartiles of RALA and B expression and impact on 
patient survival, the data were statistically significant in two 
of three data sets for RALA (Supplementary Figure 3A, B, 
Supplemental Digital Content 2, http://links.lww.com/JTO/
A483). RALB expression and impact on patient survival 
was not statistically significant when we investigate all four 
quartiles (Supplementary Figure 3C, Supplemental Digital 
Content 2, http://links.lww.com/JTO/A483). However, RAL 
protein and mRNA expression were a strong prognostic 
marker of patient survival when we compared patients with 
very high RAL expression (top 25%) with patients with very 
low RAL expression (bottom 25%).
Expression and Activation of RAL Is Related to 
KRAS Mutation in Human NSCLC Cell Lines
We next sought to determine the relationship of RAL 
expression and activity to the mutation status of its upstream 
regulator KRAS by evaluating RAL protein expression in 
FIGURE 2.  RALA and B protein and mRNA expression stratify NSCLC patient survival. Overall NSCLC patient survival as a 
function of (A) RALA and (B) RALB membrane expression as evaluated by IHC. C, Patient survival in NSCLC data sets GSE8894 
and GSE11969 (Supplementary Table 3) as a function of RALA (i) mRNA expression or (ii) risk score (see Materials and Methods 
section). D, Overall patient survival in NSCLC data set GSE4716_GPL3694 as a function of RALB expression. IHC, immunohisto-
chemistry; HR, hazard ratio; NSCLC, non–small-cell lung cancer.
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14 human NSCLC cell lines. RALA and RALB expression 
and activity were detected in all lines (Fig. 3A, C). Eight cell 
lines (H358, H2122, A549, H2009, H460, SW1573, H157, 
and Calu-6) have KRAS mutations whereas the remaining 
(H292, H322, H1703, H2228, H4006, and Calu3) are KRAS 
WT, with H4006 harboring an epidermal growth factor recep-
tor mutation. Quantification of expression by densitometry 
revealed average RALA and RALB expression was higher 
in KRAS mutant lines compared to WT lines (p = 0.043 and 
0.036 respectively, Fig. 3B). Total RALA activation was also 
higher in KRAS mutant NSCLC cell lines compared with 
WT cells (p = 0.048, Fig. 3D). In contrast, minimal RALB 
activation was observed in these lines (Fig. 3C) with no corre-
lation between total RALB activity and KRAS mutation status 
(Fig. 3D). There was no relationship between RAL para-
log expression and their corresponding activation levels 
(p = 0.08 for RALA and p = 0.23 for RALB, Supplementary 
Figure 4, Supplemental Digital Content 2, http://links.lww.com/
JTO/A483). Quantitative real-time polymerase chain reaction 
(qRT-PCR) analysis was also carried out for RALA and B mRNA 
expression in these cell lines (Supplementary Table 4). Cell lines 
with KRAS mutations trended toward high RALA (0.013 versus 
0.011) and RALB (0.0024 versus 0.0015) relative mRNA expres-
sion normalized to β-actin compared with WT lines; however, 
FIGURE 3.  RALA and RALB expression and activity in human NSCLC cell lines. A, RALA and RALB expression in 14 NSCLC cell 
lines by Western blot. Cell lines with KRAS mutation indicated with asterisks. B, Densitometric quantification of RALA and RALB 
expression shows their expression is higher in KRAS mutant NSCLC cell lines (p < 0.05, Student’s t test). C, RALA and RALB 
activation levels in the 14 NSCLC cell lines. Cell lines with KRAS mutation indicated with asterisks. D, Densitometric analysis 
revealed higher RALA activation in KRAS mutant NSCLC cell lines (p < 0.05, Student’s t test). No relationship to KRAS was found 
with RALB. E, Knockdown of RAL GTPase in H2122 cells after transient transfection with siRNA against RALA (siRALA) and B (siR-
ALB). Cells were lysed 3, 6, 9, 12, 15, and 18 days after transfection, and RAL GTPase knockdown was determined by Western 
blot. F, Loss of RALA, B or A+B reduced subcutaneous tumor growth in mice. H2122 cells were transfected with siRNA against 
RALA (siRALA), B (siRALB), and A + B (siRALA+B), injected in mice and studied for in vivo tumor growth (see Materials and 
Methods section). Luciferase siRNA transfected cells were used as control (siCTL). *p < 0.05 by Student’s t test. NSCLC, non–
small-cell lung cancer; WT, wild-type; siRNA, small interfering RNA.
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the data were not statistically significant with p = 0.11 and 0.28, 
respectively. We carried out RALA and RALB IHC on the above-
mentioned cell lines to study the relationship of RAL activation 
to RAL membrane and cytoplasmic expression and found no 
relationship.
RAL Expression Drives NSCLC 
Growth In Vitro and In Vivo
To determine whether RAL has a functional role 
in human NSCLC we evaluated the dependency of cell 
line proliferation and anchorage independent growth on 
RAL expression. For these experiments we used KRAS 
WT NSCLC cell lines and cell lines with KRAS muta-
tion in codon 12, the most common KRAS mutation site 
in NSCLC.3 RAL GTPase depletion was performed using 
specific RAL siRNAs targeting RALA, RALB, or a motif 
common to both RALA and RALB (A+B) leading to 
simultaneous knockdown.17 RAL GTPase knockdown was 
evaluated 72 hours after siRNA transduction by Western 
blotting for RALA and RALB and identified a 70% to 80% 
depletion of RALA, RALB, or both proteins in all lines 
(Supplementary Figure 5, Supplemental Digital Content 
2, http://links.lww.com/JTO/A483). Depletion of RALA, 
RALB, or both resulted in inhibition of anchorage depen-
dent and independent growth of four of six KRAS WT 
and five of six KRAS mutant NSCLC cell line (p < 0.05, 
Table 1). Loss of RALA versus RALB versus both proteins 
had different degrees of growth inhibition. Depletion of 
RALA had the greatest effect, with inhibition of monolayer 
growth in two of six KRAS WT NSCLC cell lines com-
pared with five of six KRAS mutant cell lines (p = 0.037) 
and inhibition of anchorage independent growth in one of 
six KRAS WT cell lines compared with four of six KRAS 
mutant cell lines (p = 0.04).
The impact of RAL depletion on anchorage indepen-
dent growth was greatest on the H358 (G12C KRAS) and 
H2122 (G12C KRAS) cell lines (Table 1). H2122 had near-
complete inhibition of colony formation with RALA knock-
down whereas knockdown of RALB or both proteins resulted 
in 90% and 79% inhibition. H358 had 38%, 27%, and 83% 
decrease in anchorage independent growth with similar 
RAL depletions (Table 1). To confirm these observations 
were not because of nonspecific siRNA effects, the study 
was repeated in H2122 with a second set of RAL GTPase 
siRNAs (siRALA II and siRALB II) and similar results were 
observed (Supplementary Figure 6, Supplemental Digital 
Content 2, http://links.lww.com/JTO/A483). Interestingly, 
investigation of the PI3K/AKT and MAPK pathways, which 
also signal downstream of KRAS, revealed that these alter-
nate pathways had minimal to no activation in NSCLC cell 
lines that carry the KRAS G12C mutation (Supplementary 
Figure 7, Supplemental Digital Content 2, http://links.lww.
com/JTO/A483).
The H2122 cell line was then used to study RAL’s effect 
on tumor growth in vivo. H2122 cells were transfected with 
control, RALA, RALB, or RALA+RALB siRNAs and RAL 
expression evaluated at multiple time points after transfection 
(Fig. 3E). RAL expression was found to be suppressed for up 
to 15 days (Fig. 3E) supporting the notion that in vivo tumor 
growth would be suppressed during this time frame. With 
these data in hand, we repeated the depletion in H2122 cells 
and inoculated them into mice 2 days after transfection. As 
shown in Figure 3F, transient knockdown of RALA, RALB, 
or both proteins had significant impact on tumor growth 
TABLE 1.  Monolayer and Anchorage-Independent Growth of NSCLC Cell Lines with Knockdown of RAL GTPase
Cell Line Histology KRAS
RALA Knockdown RALB Knockdown RALA+B Knockdown
Monolayer 
Growth
Anchorage- 
Independent 
Growth
Monolayer 
Growth
Anchorage- 
Independent 
Growth
Monolayer 
Growth
Anchorage- 
Independent 
Growth
H322 Adenocarcinoma WT −52%* −41.2%* −33%* −42.3%* −46%* −39%*
H1703 Adenocarcinoma WT N.S. N.S. N.S. N.S. N.S. −52.3%*
H2228 Adenocarcinoma WT N.S. N.S. N.S. N.S. N.S. N.S.
H292 Mucoepidermoid WT N.S. No colony −23%* No colony N.S. No colony
H4006 Adenocarcinoma WT N.S. No colony N.S. No colony N.S. No colony
Calu3 Adenocarcinoma WT −33%* No colony −36%* No colony −39%* No colony
H2122 Adenocarcinoma G12C −91%* −97%* −61%* −89.2%* −42%* −79.6%*
H358 Adenocarcinoma G12C −24%* −38%* N.S. −27.6%* −86%* −83.4%*
A549 Adenocarcinoma G12S −26%* −24.5%* −29%* N.S. −27%* −51.3%*
H2009 Adenocarcinoma G12A −25%* −35%* −19%* −28.7%* 28%* −15.8%*
H157 Squamous cell G12R −24%* N.S. −19%* N.S. N.S. N.S.
SW1573 Alveolar cell G12A N.S. No colony N.S. No colony N.S. No colony
Cells were transfected with siRNA against RAL GTPase and plated for proliferation and anchorage-independent growth assay (see Materials and Methods section). Monolayer 
growth was measured 4 days after transfection with results representing the mean of 2–3 studies with 4–5 replicates per cell line. Anchorage-independent growth results are mean of 
three experiments. (+) indicates increase compared with control. (−) indicates decrease compared with control. “N.S.” is no significant change. “No colony” indicates cells did not 
exhibit anchorage-independent growth.
NSCLC, non–small-cell lung cancer; WT, wild-type; siRNA, small interfering RNA.
*p < 0.05 (Student’s t test).
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with a 94%, 81%, and 81% decrease, respectively, at 20 days 
(p < 0.05). Together, these data suggest that RAL expression 
is especially important for tumor growth in NSCLC cell lines 
harboring G12C KRAS mutations.
G12C KRAS Mutation Regulates Anchorage 
Independent Growth through RAL
Functional assays revealed cell lines with KRAS G12C 
mutation were most dependent on RAL GTPase for tumor 
processes (proliferation, anchorage independent growth; 
Table 1). Therefore, to determine whether KRAS G12C muta-
tion results in tumor progression that is specifically depen-
dent on the RAL pathway, H2228 cells were stably transfected 
with KRAS WT, KRAS G12C mutant (found in H2122), and 
KRAS G12V mutant (Fig. 4A). The H2228 cell line was cho-
sen because it is KRAS WT, has high RALA and B expression 
but its anchorage independent growth is independent of RAL 
expression (Table 1). H2228 cells overexpressing KRAS G12C 
and G12V mutants have high KRAS activation compared 
with cells transfected with KRAS WT (Fig. 4B). An increase 
in RAL activation in H2228 cells overexpressing the KRAS 
G12C mutant was also seen when compared with H2228 cells 
overexpressing KRAS WT and KRAS G12V mutant (Fig. 4C, 
D), suggesting increased signaling through RAL in cells hav-
ing KRAS G12C mutation. Importantly, KRAS G12C and 
G12V overexpressing cells had a 48% and 127% increase in 
anchorage independent growth compared with KRAS WT (p 
< 0.05), respectively. This increase in anchorage independent 
FIGURE 4.  The role of RAL and KRAS in tumor growth. A, KRAS expression in H2228 cells stably transfected with empty vector 
(CTL), KRAS WT, KRAS G12C and G12V mutants (KRAS G12C and KRAS G12V) detected by Western blot. B, KRAS activation 
in the engineered H2228 cell lines as determined by RAS activation enzyme-linked immunosorbent assay (see Materials and 
Methods section). *p < 0.05 by Student’s t test. C, RALA and B activation observed by Western blot in H2228 cells transfected 
with empty vector (CTL), KRAS WT, and KRAS G12C and G12V mutants (KRAS G12C and KRAS G12V) (see Materials and 
Methods section). D, Densitometric analysis of RALA and B activation observed in (C). Asterisk and pound indicate p < 0.05 for 
RALA and B by Student’s t test. E, RALA and B loss observed by Western blot after transfection of engineered H2228 cell lines 
with siRNA targeting both RALs (siRALA+B). A luciferase siRNA transfected cells are used as control (siCTL). F, Anchorage inde-
pendent growth of engineered H2228 cell lines after loss of RAL GTPase (*p < 0.05 by Student’s t test). WT, wild-type; siRNA, 
small interfering RNA.
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growth for cells overexpressing KRAS G12C was RAL depen-
dent, as shown by a 83% inhibition in anchorage independent 
growth with siRNA-mediated depletion of RALA+RALB in 
H2228 cells expressing KRAS G12C compared with 44% and 
34% inhibition in cells overexpressing WT KRAS and KRAS 
G12V mutant (Fig. 4E, F). This suggests that NSCLC tumors 
with a KRAS G12C mutation become more reliant on the 
RAL pathway for tumor growth.
Contributions of KRAS and RAL in 
NSCLC Tumor Progression
These data suggest RAL expression mediates KRAS-
driven NSCLC growth. This extends prior work showing 
RAL is required for KRAS-induced tumor formation.20 To 
determine whether this relationship is supported by clinical 
data, we examined the relationship of RAL paralog expres-
sion to that of KRAS mRNA expression in regard to survival 
of NSCLC patients. In data set GSE8894 where we found 
high RALA mRNA predicted poor patient outcome (Fig. 2C), 
stratification of patients by KRAS and RALA mRNA expres-
sion status found high KRAS and RALA mRNA expression 
was associated with poor recurrence-free survival compared 
with patients with high KRAS and low RALA mRNA expres-
sion (p = 0.031; Fig. 5A). In addition, analysis of data set 
GSE11969 where we had previously found high RALA risk 
score predicted poor patient outcome (Fig. 2C) suggested that 
KRAS risk score impacts the prognostic stratification driven 
by the RALA risk score with high RALA and KRAS mRNA 
expression now associated with poor overall survival com-
pared with patients with high RALA and low KRAS mRNA 
expression (p = 0.022; Fig. 5B). These analyses indicate that 
KRAS and RALA can contribute independently to patient 
prognosis despite their canonical hierarchical relationship. 
A similar analysis was carried out for KRAS and RALA in 
GSE4716_GPL3694 in which high RALB mRNA expression 
predicted poor overall patient survival (Fig. 2D) but none of 
the interactions were statistically significant.
We also evaluated the interaction of RALB and KRAS 
expression in the two data sets where high RALA mRNA 
(GSE8894) or risk score (GSE11969) is predictive of poor 
patient outcome but no interaction was observed. However, 
in data set GSE4716_GPL3694 patients with high KRAS and 
RALB mRNA expression had poor overall survival compared 
with patients with high KRAS and low RALB mRNA expres-
sion (p = 0.028; Fig. 5C). Patients with high KRAS and RALB 
mRNA expression trended (p = 0.082) toward poor overall 
survival compared with patients with low KRAS and high 
RALB mRNA expression (Fig. 5D). Because KRAS mutation 
status of patients in these data sets was unknown, we could not 
investigate the survival information carried by RAL GTPase 
in patients carrying KRAS mutations.
DISCUSSION
Recently RAL GTPase null and conditional knockout 
mice were crossed with mice developing KRAS-driven NSCLC 
to show that RAL is important in KRAS-driven pulmonary 
FIGURE 5.  RAL and KRAS mRNA 
expression and risk score stratify 
overall and recurrence-free survival in 
NSCLC patients. A, Recurrence-free 
survival in NSCLC data set GSE8894 
as a function of RALA mRNA expres-
sion in patients with high KRAS 
mRNA expression. B, Patient overall 
survival in NSCLC data set GSE11969 
as a function of KRAS risk score in 
patients with high RALA risk score. C, 
Patient overall survival in NSCLC data 
set GSE4716_GPL3694 as a function 
of RALB mRNA expression in patients 
with high KRAS mRNA expression. D, 
Patient overall survival in NSCLC data 
set GSE4716_GPL3694 as a function 
of KRAS mRNA expression in patients 
with high RALB mRNA expression. 
NSCLC, non–small-cell lung cancer; 
HR, hazard ratio.
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tumorigenesis.15 PI3K/AKT and MAPK pathways are also 
important for KRAS-driven tumors.5 Here we move the field 
forward by using IHC, transcriptomic and human cell line–
based functional analysis to investigate the prognostic infor-
mation carried by RAL GTPase and its role in NSCLC tumor 
progression as a function of KRAS. We began our investiga-
tions by evaluating the prognostic information carried by RAL 
protein and mRNA expression in human cancers. IHC analy-
sis of RAL protein expression revealed that RALB cell mem-
brane expression is a negative prognostic marker in NSCLC 
(Fig. 2B). Because membrane localization suggests the GTPase 
is in an active state14,20,22,23 we suggest that active RALB is a 
prognostic marker for decreased survival in NSCLC. In addi-
tion, patients with high RALA membrane expression trended 
toward poorer overall survival but the data were not statistically 
significant (Fig. 2A). Because RAL cytoplasmic expression 
(data not shown) and total RAL expression (Supplementary 
Figure 2C, D, Supplemental Digital Content 2, http://links.lww.
com/JTO/A483) are not predictive of survival we can advocate 
that membranous RAL is the functionally active form of RAL 
in NSCLC patient tumors. This protein analysis was followed 
up with an evaluation of RALA and RALB mRNA expression 
where higher levels were associated with shorter recurrence-
free and overall survival (Fig. 2C, D). Interestingly, we noted 
that in the patient data sets (IHC or microarray) either RALA 
or RALB primarily carried the prognostic information (Fig. 2). 
We conclude that RAL carries important clinical information. 
However, we speculate that in each tumor only one of the two 
RAL paralogs is functionally dominant.
Investigation of the functional role of RAL GTPase in 
NSCLC revealed that loss of RALA, RALB, or both resulted 
in variable changes in monolayer proliferation, anchorage 
independent growth, and subcutaneous tumor formation in 
NSCLC cell lines (Table 1, Fig. 3E, F). RALA expression 
seemed more important in driving growth in KRAS mutant 
NSCLC cell lines compared with KRAS WT cell lines, sug-
gesting that in this panel of NSCLC cell lines RALA is the 
functionally dominant isoform driving KRAS-dependent 
tumor growth (Table 1, Fig. 3A, B). Interestingly, cell lines with 
a G12C KRAS activating mutation had greater dependence on 
RAL for anchorage independent growth compared with lines 
with other codon 12 mutations or KRAS WT (Table 1, Fig. 4). 
Furthermore, NSCLC cell lines (H2122 and H358) with the 
G12C mutation had minimal activation of PI3K/AKT and 
MAPK pathways downstream of RAS (Supplementary Figure 
7, Supplemental Digital Content 2, http://links.lww.com/JTO/
A483). H2122 has no activation whereas H358 has minimal 
activation of these alternate pathways and high activation of 
RAL GTPase. The lack of alternate pathway activation in these 
cell lines suggested that they are dependent on RAL signaling 
for their tumorigenic phenotype whereas those cell lines with 
activation of PI3K/AKT and MAPK pathways downstream 
of KRAS are partially dependent or not dependent on RAL 
GTPase because of the availability of these alternate pathways 
for tumor progression (Table 1). A549 was the only exception 
to this trend (Supplementary Figure 7, Supplemental Digital 
Content 2, http://links.lww.com/JTO/A483). This line does 
not have activation of PI3K/AKT and MAPK pathways yet 
is only marginally dependent on RAL expression for tumori-
genicity (Table 1). This may be explained by the finding that 
A549 is independent of RAS activity for tumor growth.24 We 
gained further support for the notion that KRAS G12C muta-
tions drive tumor progression via RAL GTPase by stably over-
expressing KRAS G12C mutant construct in H2228 NSCLC 
cell line, which is KRAS WT, and showing RAL loss inhibits 
anchorage independent growth (Fig. 4). Our findings con-
firmed and validated initial observations made by Ihle et al.16
To understand the functional correlation between RAL 
paralogs and KRAS in NSCLC we examined RAL–KRAS 
statistical interactions in microarray data sets. This analysis 
was limited by the lack of KRAS mutation status and thus we 
made the assumption that tumors with high KRAS expression 
had concomitantly elevated activation. Our analysis revealed 
that both KRAS and RAL expression are determinants of 
patient prognosis and suggest that RAL function in NSCLC 
is driven only in part by KRAS whereas KRAS also activated 
other prognostic pathways (Fig. 5). This observation is consis-
tent with the aforementioned finding in the NSCLC cell line 
panel where we observed activation of PI3K/AKT and ERK 
pathways in cells that were less dependent on RAL expres-
sion (Table 1, Supplementary Figure 7, Supplemental Digital 
Content 2, http://links.lww.com/JTO/A483).
These studies have significant implications for human 
NSCLC, such as the identification of their RAL dependence, 
the identification of RAL as a potential therapeutic target in 
this disease, and the ability to stratify patients for future anti-
RAS or anti-RAL therapy by virtue of RAS and RAL expres-
sion and mutation status. Because inhibitors of downstream 
RAS signaling pathways such as PI3K/AKT and MAPK path-
ways are in clinical investigation in KRAS mutant NSCLC,5 
these studies serve as a strong impetus for the development of 
anti-RAL therapeutics to suppress KRAS-driven signal propa-
gation and improve poor clinical outcomes seen in NSCLC 
patients.
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